Challenges in the management of obesity.

BACKGROUND: Obesity is a chronic, multifactorial disease associated with significant metabolic, physical, and psychosocial complications. Although advances in pharmacologic therapy-particularly glucagon-like peptide-1 (GLP-1)-based agents-have expanded treatment options, challenges persist in the effective management of obesity. SOURCES OF MATERIAL: This paper reviews current literature, including clinical trial data, national guidelines, and recent policy updates, to identify key barriers to optimal obesity management. Primary sources include studies and reviews published between 2021 and 2025, as well as data from the Centers for Medicare & Medicaid Services (CMS), the U.S. Food and Drug Administration (FDA), and the World Health Organization (WHO). ABSTRACT FINDINGS: There are 4 major challenges in obesity management highlighted in this paper: (1) determining which healthcare providers should prescribe and manage obesity pharmacotherapy, (2) the necessity for lifelong treatment to sustain benefits from pharmacotherapy, (3) inconsistent third-party reimbursement that limits patient access, and (4) drug shortages compounded by high demand and direct-to-consumer (DTC) marketing. GLP-1-based agents demonstrate substantial weight reduction but require ongoing therapy to maintain outcomes. Reimbursement barriers persist across Medicaid, Medicare, and commercial plans, while drug shortages and compounded formulations pose safety and ethical concerns. CONCLUSION: Effective obesity management requires a coordinated, multidisciplinary approach supported by equitable insurance coverage and regulatory oversight. Providers must balance pharmacotherapy with behavioral and lifestyle interventions and educate patients on the risks of unapproved or compounded products. Addressing these systemic challenges will be essential to ensure sustained, safe, and accessible care for individuals with obesity.